Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trial
ObjectiveVunakizumab, a novel IL-17A inhibitor, has demonstrated satisfactory efficacy and safety for the treatment of moderate-to-severe plaque psoriasis. This analysis aimed to assess the impact of treatment interruption on the efficacy and safety of vunakizumab in the treatment of this disease.Me...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2026-01-01
|
| Collection: | Frontiers in Immunology |
| Sujets: | |
| Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1639049/full |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|